←
Julian Chun1,012 posts
Julian Chun avatar

Julian Chun

@jongichun
◷ Joined October 2009▧ 157 Photos and videos
EHRAPresident avatar
⟳ Julian Chun retweeted
EHRAPresident@EHRAPresident·Oct 19

Do oesophageal temperature probes actually make left atrial ablation safer and are we still using them? That’s the question behind the new EHRA Scientific Initiatives Committee survey on the contemporary use of oesophageal temperature probes (ETPs) during left atrial ablation and the subject of our latest #EHRA_SICsays conversation with @AriSultanEP. 232 physicians from 37 countries responded and the picture is far from uniform. ETPs are used predominantly during thermal ablation, while their use with pulsed field ablation is uncommon. Even when probes are used, temperature thresholds and the response to temperature excursions vary considerably between centres. The key issue isn’t simply whether we monitor temperature. It’s what that monitoring actually achieves. Current randomized and observational evidence has not established that ETPs prevent oesophageal injury or atrio-oesophageal fistula, and 56% cited lack of evidence for AEF prevention as a reason for not using them. Meanwhile, the growing use of PFA is reshaping oesophageal protection strategies altogether. 🎙️ Watch the discussion with @AriSultanEP 👇 📄 Read the full manuscript: bit.ly/4hGfaXZ Does oesophageal temperature monitoring still have a place in your left atrial ablation workflow? #EHRA_SICsays #EHRA_ESC #EPeeps #AtrialFibrillation #CatheterAblation #PulsedFieldAblation #Electrophysiology @LauraPerotta @JarkkoKarvonen @jongichun @micaela_ebert @DrCherylTeresEP @HaranBurri @veramasloo @drtahasahin @AugustoMeretta @JacopoImberti @cespon_maria @jadczyk @Fede79Miglio @CarolRemme @LA_Stanciulescu @VerenaTscholl @Amar__taha @mattans5 @AmrAbdin10 @JuliaCTourigny @DrMarkMills @RachelterBekke @FraSantoroMD @Pierre_Olt @cris_lozano @LinaMarcantoni @ChristianHeeger

4:46
Julian Chun avatar
⟳ Julian Chun retweeted
Julian Chun@jongichun·Apr 1

BIG BIG 🙏🏻🙏🏻🙏🏻 to all authors and centers for contributing to this joint work. Born and discussed in the EHRA SIC - executed by Sergio Castrejon et al. ✅Now, we have realistic information on stroke risks linked to AF ablation!

It’s published! Likely one of the largest studies on ablation ever published. A study so large, they even covered New Zealand! Congratulations to the organisers of this epic effort #EPeeps

Julian Chun avatar
Julian Chun@jongichun·Sep 29

Pacing LAA….! What happens and why..?

Post attachment
0:09
EHRAPresident avatar
⟳ Julian Chun retweeted
EHRAPresident@EHRAPresident·Sep 2

Who is behind #EHRA_ESC? 👋❤️ The new EHRA Board brings together colleagues working across the many areas that make our community thrive: 🎓 Education 🔬 Science ❤️ Patient initiatives 🤖 Digital & AI 🌍 Diversity & international collaboration 🧬 Genetics 🌱 Young EP 📣 Advocacy & communication 🎤 Congress & more And behind them? Committees, volunteers and members sharing their expertise, energy and ideas. 🤝 EHRA is much more than its President or Board — it’s a diverse, international community working together to shape the future of electrophysiology. ⚡🌍❤️ #EHRATopicWeek #EHRA_ESC #EHRAEducation #ScientificInitiatives #DigitalHealth #PatientInitiatives #YoungEP #ECommunications #EHRA2027 #Leadership #Electrophysiology

Post attachment
Mark Mills avatar
⟳ Julian Chun retweeted
Mark Mills@DrMarkMills·Jun 12

Our new publication in Europace 📖 Diversity, equity and inclusion in arrhythmia care: A European Heart Rhythm Association survey Link: academic.oup.com/europace/ad… @jongichun @ChristianHeeger @Mel_Gunawardene @LauraPerrottaEP #EHRA_SIC

Roderick Tung avatar
⟳ Julian Chun retweeted
Roderick Tung@DrRoderickTung·Jun 6

Great to be back in China 🇨🇳 It’s real, I’ve seen it with my own eyes. The robots are here. #CHRS2026

0:33
Circulation avatar
⟳ Julian Chun retweeted
Circulation@CircAHA·Jun 4

In this sham-controlled trial of 60 patients with symptomatic atrial fibrillation, pulsed field ablation (PFA) was superior to sham in reducing arrhythmia recurrence & burden and improving QOL. ahajrnls.org/4o6FTA1

Post attachment
Heart Rhythm Society avatar
⟳ Julian Chun retweeted
Heart Rhythm Society@HRSonline·May 3

Hear from #HRS2026 #SciComms correspondent Andres Castillo, MD as he discusses late-breaking trial "Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study" with @jongichun. Learn more about the LBCTs here: bit.ly/4efh0PE

1:22
Heart Rhythm Society avatar
⟳ Julian Chun retweeted
Heart Rhythm Society@HRSonline·May 1

Hear from #HRS2026 #SciComms correspondent @veramasloo as she interviews @jongichun about late-breaking clinical trial "A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent AFib" (AVANT GUARD). Learn more about the LBCTs here: bit.ly/4efh0PE

3:02
EHRAPresident avatar
⟳ Julian Chun retweeted
EHRAPresident@EHRAPresident·Apr 26

#EHRAroundTheGlobe is still at #HRS2026 in Chicago 🇺🇸 @jongichun joins us for a conversation on one of the hottest topics in EP right now — the PFA Summit and the newly released PFA consensus document. Pulsed field ablation is reshaping how we approach AF ablation. Here's where the science and the guidelines stand today 👇

2:00
Jason Andrade avatar
⟳ Julian Chun retweeted
Jason Andrade@DrJasonAndrade·Apr 25

More than 10 years ago Oussama and I started our journey of investigation, trying to the define the optimal first treatment for patients with atrial fibrillation.  Separately we pursed randomised studies in populations with treatment-naive paroxysmal AF.  Five years ago we presented our RCTs in the paroxysmal AF population, which ended up sitting side by side in the same issue of the New England Journal of Medicine.  nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE… Since then we have been working together to examine the same question of optimal initial therapy, but instead looking at patients with more advanced forms of atrial fibrillation.  Today Oussama presented the results of the AVANT-GUARD study, which definitively demonstrated the value of initial catheter ablation in the treatment naive persistent AF population. Like EARLY-AF, AVAT GUARD used implantable cardiac monitors to evaluate arrhythmia endpoints   Like EARLY-AF - initial catheter ablation reduced recurrences in AVANT GUARD by about 50%, which was about 25% in absolute terms. To put this another way, only 4 patients need to be treated with ablation to prevent a recurrence of arrhythmia.  However, binary recurrence doesn’t tell the whole story. Because we had loop recorders we were able to assess the time spent in AF (or AF burden). In this regard significantly more patients had none or negligible burden after ablation (<0.1%), with significantly more AAD treated patients having a very high burden (>5%). This is important as AF burden is associated with clinical outcomes such as hospitalisation. In terms of risk - the rates of any adverse event or serious adverse event were comparable between randomised arms. Highlighting that persistent AF patients with high CHADS-VASc score are high risk irrespective of treatment provided. This is important as we reflect on treatment options as part of shared decision-making. Congratulations to Oussama for the presentation and leadership, to the co-investigators and study sites for their participation and dedication, and a huge thank you to the Boston Scientific team for their support and commitment to advancing science.  To end, I want to acknowledge and thank Oussama for this shared journey, I’m grateful for our collaboration and friendship, and look forward to what we will do next.

NEJM@NEJMApr 25

Presented at #HRS2026: In patients with persistent atrial fibrillation, first-line treatment with pulsed field ablation reduced the recurrence of atrial arrhythmias at 12 months as compared with antiarrhythmic drugs. Full AVANT GUARD trial results: nejm.org/doi/full/10.1056/NE… @HRSonline

Post attachment